The immune checkpoint VISTA is associated with prognosis in patients with malignant uveal melanoma

Introduction Uveal melanoma (UM) is a rare yet deadly tumor. It known for its high metastatic potential, which makes it one of the most aggressive and lethal cancers. Recently, immune checkpoints such as Programmed cell Death protein-1 (PD1) Cytotoxic T-Lymphocyte-Associated significantly increasing patient survival in multiple human cancers, especially cutaneous melanoma. However, patients with UMs were excluded from these studies because their molecular characteristics, tend to be widely different those This study aimed analyze expression V domain Ig Suppressor T-cell Activation (VISTA), novel checkpoint, evaluate prognosis significance correlation PD1 CTLA-4. Methods Evaluation VISTA, CTLA-4, was performed through TCGA database analysis immunohistochemistry using two independent cohorts primary malignant UM. Results discussion Our results showed that VISTA associated tumor aggressiveness, T exhaustion, shortest median overall among patients. Surprisingly, protein negative all patients, whereas CTLA-4 advanced stages. findings suggest may prognostic marker an attractive treatment strategy immunotherapy Exploring profile predict response lead improvement precision therapy uveal